focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Broker Rating 70p. What's not to like.
And 474 parsortix blood samples analysed so at least £474k in the coffers….
Https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.34978
Just look at the Companies mentioned in this article:-
***Elena Ioana Braicu receives research funding from Bayer, Roche Diagnostics, Tesaro, GSK, and AstraZeneca and personal fees from AstraZeneca, Clovis, GSK, Tesaro, EISAI, RochePharma, and Roche Diagnostics. Elena Ioana Braicu is a Feodor Lynen fellow of the Humboldt Foundation and a participant in the Charité Clinical Scientist Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of Health.
***Philipp Harter receives research funding from Astra Zeneca, Roche, GSK, Genmab, DFG, European Union, DKH, Immunogen, Seagen, Clovis, and Novartis and honoraria from Amgen, Astra Zeneca, GSK, Roche, Sotio, Stryker, Zai Lab, MSD, Clovis, Eisai, Mersana, and Exscientia.
***Philipp Harter is ******an advisory board member******* for Astra Zeneca, Roche, GSK, Clovis, Immunogen, MSD, Miltenyi, Novartis, and Eisai!!!!!!!!!!!!!!!*************.
All IMHO.
Agl will go like redx. Bod will take this out of aim
Trading update due and also updates on other contracts. Gla
I see these hitting 20.00 + in the short term and bought some more
250000 buy printed from last friday . Peep paid 15.15.
TGTD - Angle don't need 6m in new customer contracts to meet the 6m revenue target. As well as the new contracts they have:-
- A base of existing lab services customers from 2023 whose work extends into 2024 (and may well have follow on contracts already in place).
- Parsortix device & cassette sales which will also be generating revenue (they aren't going to announce the sale of each machine)
- Other product sales (the new kit)
The new customer announcement are just one part of the revenue picture. Hopefully we will get some good insight into the scale / trajectory of the bigger picture in the imminent results.
Loads….yet you sold shares last, as you (claimed) you did when it was. >18p
What’s your average here EC?
One wonders what others are in the pipeline.
There are thousands of Pharma Co's IN THE WORLD. Food for thought TwoGood2Die, is it not!!! LOL!
I think there will be LOADS in the next 4 months. LOADS.
All IMHO.
The Board really should demand that Newland’s salary be cut back as he persists in misleading investors. Outrageous that he was allowed to stick his finger in the air and guess at a tripling of revenues and then provide absolutely no solid reasoning as to why.
Nearly half the year gone and no sign of the £6m in order to extend the cash runway to Q2 next year.
It was around this time last year that the last cash placement was raised!
Miavoce
Revenue is cash at the end of the day is it not?
The company have confirmed there’s a funding gap. It would be very optimistic to think that since Novembers trading update we’ve not only found the trebling £6m of revenue, but surpassed that to such an extent that we’ve extended the runway. We are indeed speculating about the performance this year but there’s no RNS to point to around material revenue. I suspect we won’t hit the £6m and thus the runway is shorter.
Hi TGTD, it is incorrect to say that the company needs a minimum of 12 months cash to meet going concern requirements for the auditor's to sign off the 2023 accounts in May. There is no such requirement for a going concern status.
What Angle need to be able to demonstrate is that either their revenue + cash will be sufficient to keep the company operating, or that their revenue + cash + a feasible cash raise (if necessary) will be sufficient.
Whether / when a cash raise is needed will become much clearer when we get some current trading / outlook info with the imminent results publication. Until then everything is pure speculation.
When is the next cash placement andvat what price...🤔
It's now getting pretty obvious that the additional £6m of revenues that Newland spouted finger wagging style in order to extend the cash run way till Q2 2025 are not going to materlise soon.
We now have RNS's proclaiming success stories but when you look for the financials they are just tiny miniscule amounts.
It seems these are designed solely to prop up the share price ahead of an imminent cash placement imho.
With cash dwindling to around £7m or £8m its about now thar news on a fund raise would be expected as you need a minimum of 12 months cash to meet going concern requirements for the auditor's to sign off the 2023 accounts in May.
It's already noted in the RNS on the 22nd :
"We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions."
Hopefully more news next week. Well suppressed by mms. Better days next week. Gla
Angle now have both Eisia In. (top 100 Japanese Co) and Astrazeneca (FTSE 100 Co.) on their books.
Acorns grow to oak trees............
Where did you get the $232 billion from! Thin air?
Almost all buys but price flat
IMHO the sp should be 18p+, absolute minimum. The bottom line is the Parsortix machine did not sell as well as they had hoped after FDA clearance. The problem was Angle hoped/expected the Pharma clients to do the work needed after the Parsortix machine had caught the circulating tumour cells to test. Also, this is such "cutting edge technology" that some labs simply did not have the technical knowhow to do the assays. Angle have now have a HER2 assay, a PD-L1 assay, a portrait flex assay, and a DNA Damage Response one. Also, the Portrait+ CTC kit which makes using the machine easier and standardises the stains used. These are now driving the Services side of the business which demonstrate the results the Parsortix machine can deliver, and no doubt increases sales of the Parsortix machine.
8th Apr 2024 7:00 am RNS Parsortix HER2 assay showcased at AACR 2024
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
5th Dec 2023 7:00 am RNS ANGLE launches Portrait+ CTC kit at SABCS
https://www.lse.co.uk/rns/AGL/angle-launches-portrait-ctc-kit-at-sabcs-5mzhyiaiggmk83j.html
9th Nov 2023 7:00 am RNS Launch of PD-L1 test to support cancer studies
https://www.lse.co.uk/rns/AGL/launch-of-pd-l1-test-to-support-cancer-studies-o8m4cvtjt6ft9a9.html
4th Sep 2023 7:00 am RNS ANGLE launch of Portrait Flex assay
https://www.lse.co.uk/rns/AGL/angle-launch-of-portrait-flex-assay-q8vjkxoz5ew8ywd.html
25th May 2023 7:00 am RNS Pharma services contract with Artios Pharma
https://www.lse.co.uk/rns/AGL/pharma-services-contract-with-artios-pharma-mjim4s7jtk1clj5.html
All IMHO
Last Trading Update
Revenue recognised for 2024 is expected to treble compared to 2023 with the growth of distributor sales, and with the planned launches of the Portrait PD-L1 test (services), see separate announcement today, the Portrait+ antibody staining kit (products), and the Parsortix BiDetectTM DNA solutions combining ctDNA and CTC-DNA analysis (products and services) all contributing to the Company's sales growth ambitions.
Business update - Streamlining services business extends cash runway
With the expected growth in molecular solutions requiring investment and considering ongoing adverse market conditions, we have made the decision to streamline our Services operations by closing the US clinical laboratory and focusing on a single UK-based centre of excellence. We have developed solutions for sample stability so that the physical location of the laboratory does not limit its capability to service customers across different geographies. The streamlining will enable us to focus our investment in multiple molecular platforms for different applications in a single location without duplicating these significant costs.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The build-up of revenues has been slower than hoped but is moving in the right direction and the Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."
Berenberg Bank reaffirmed their buy rating on shares of ANGLE (LON:AGL – Free Report) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 70 ($0.86) target price on the stock